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poorly appreciated the professional performance of pharmacists. Therefore, 
raising the awareness about the important role of pharmacist in providing public 
health is warranted.  
 
PHS119  
PROFILE OF PATIENTS USING IMMUNOBIOLOGICAL IN A HEALTH PLAN 
OPERATOR, FORTALEZA, BRAZIL: ECONOMIC AND PHARMATHERAPEUTICS 
INDICATORS  
Reis H1, Magalhães DDP2, Sartori DP2, Vieira JB2, Alcantara ACDC2, Filho AEAM2, Barsi 
UD2, Alencar JLL2, Ferreira J3, Fonseca DB2 
1UNIMED, Fortaleza, Brazil, 2Unimed Fortaleza, Fortaleza, Brazil, 3UFC, Fortaleza, Brazil  
OBJECTIVES: To profile the use of an operator in immunobiological 
supplemental health Fortaleza - Brazil, to identify the most prescribed 
therapeutic regimens and costs. METHODS: Cross-sectional study in two 
hospitals accredited service provider, from March to November/2012. Data were 
recorded by medical expertise in computerized management system (Sabius®) 
performed after the medical consultation. Later, these were entered in Microsoft 
Excell 2007 and analyzed by pharmacists auditors. The cost was calculated from 
the value contained in Brasíndice Unit 765, using the Consumer Price Max. The 
doses used for rheumatoid arthritis Etanercept 50 mg, 40 mg Adalimumab, 
abatacept 750 mg, 300 mg infliximab, 560 mg Tocilizimabe, Rituximab 1g and 
Golimumab 50 mg based on a 70 kg adult. RESULTS: We analyzed 64 patients 
with a mean weight 67 kg, of which 70.31% (n = 45) were women aged 30-59 years 
whose most frequent indications were rheumatoid arthritis (n = 33, 51.56%) and 
ankylosing spondylitis (n = 19; 29.69%). The most immunobiological commonly 
prescribed were Infliximab (n = 36; 56.25%), Tocilizimabe (n = 11, 17.19%), 
abatacept, and Rituximab (n = 8; 12, 50%) and golimumab (n = 1, 1.56%). It was 
observed that 67% (n = 43) patients were naïve immunobiological and 33% (n = 
21) initiated with anti-TNF, whereas 61.9% (n = 13) moved into one another with 
immunobiological mechanism of action and 38.1% (n = 8) continued with an 
anti-TNF, changing only the drug. The average cost of treatment/dose first line 
was R$ 6,068.91 and the second line was R$ 9,590.06, resulting in an incremental 
cost/dose of R$ 3,521.16 (36.72%). CONCLUSIONS: Knowledge of costs and 
pharmacotherapeutic profile becomes important for planning strategies aimed at 
streamlining and optimization of these drugs on quality of care.  
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MEDICAL RE-ADMISSIONS AT THE ROYAL LONDON HOSPITAL – PATIENT 
SPECIFIC AND DISEASE SPECIFIC FACTORS AT ONE WEEK AND ONE MONTH  
Ma L, Wilkinson H, Saleh A, Raichura H, Wilson L, Emmanuel J 
Royal London Hospital NHS Trust, London, UK  
OBJECTIVES: The Royal London Hospital is a teaching hospital in East London, 
UK. We hypothesised that medical patients with multiple co-morbidities and 
complex disease are likely to present with a new diagnosis when re-admitted 
within a month. Further, re-admission within a week is likely to be related to the 
initial diagnosis. METHODS: We conducted a retrospective audit of all non-
elective adult acute medical admissions over a 6 week period during 2012. We 
collected information on patient demographics, ICD-10 diagnosis, length of 
hospital stay, along with readmissions within one week and one month. We 
reviewed the original and subsequent electronic discharge summaries. We 
highlight patient specific and disease specific factors. RESULTS: There were a 
total of 124 readmissions from the original audit (n=859). A large proportion (40%) 
of all readmissions were in the elderly (over the age of 70). There were 73 (59%) 
readmissions within 1 month, and 37 (30%) within a week. Fourteen patients 
(11%) were readmitted within a week, and again within a month. COPD (33%), PE 
(29%), sepsis (26%) and cellulitis (24%) had the highest re-admission rates. Our 
audit points to a 14.4% readmission rate in our cohort. We aim to address the 
precipitating factors in our new physician led ambulatory care clinic. We 
highlight the bed days saved through such a clinic. CONCLUSIONS: Contrary  
to our hypothesis readmissions within a month were related to the original 
diagnosis, interestingly this was less so when re-admitted within a week. Our 
audit has helped highlight the need for better community management  
plans prior to discharge. This has led to closer links with the  
Community Rehabilitation and Support Team (CReST) in order to reduce 
readmission rates.  
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DO PATIENTS NEED TO BE ACCOMPANIED IN ICU WARDS?  
Zhang Y1, Zhang HY2, Qiao Y1 
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OBJECTIVES: For treatment needs, accompany is limited for ICU patients. A 30-
minute visit a day is allowed for their families. However, mental disturbance 
have been reported in ICUs. Actually, patients suffer from not only diseases but 
also loneliness in the units. The study was conducted to answer the question 
whether ICU patients need to be accompanied? METHODS: A questionnaire 
survey consisting of 3 questions about the attitude to accompanies in ICU was 
conducted in General Hospital of Shenyang Military Area in China. The 3 
questions are: 1) Do you need an accompanier when treated in ICU? (Yes/No); 2) 
If you need, who will be the candidate? (A family member/A paid nursing staff/A 
relative or friend/Anyone available); 3) How long do you need to stay with your 
family members each day in ICU? (Half an hour/One hour/Half a day/All day). 
After repeatability test, the questionnaire was filled by patients randomly 
selected in ICU wards of cardiology and general medical wards from January 1, to 
August 31, 2011. Chi-square tests were used to compare the choices between 
patients from different wards, of different gender and age. RESULTS: 
Repeatabilities for the 3 questions were 0.742, 0.783, and 0.785. Totally, 142 
patients were involved in, including 69 ICU patients and 73 general patients, 117 
males and 25 females, 53 young & middle aged (≤60 )and 89 old ones (>60). Fifty-
seven percent of the patients needed accompaniers in ICU, 86.6% of the patients 
chose family members as the candidates, 74.6% of the patients needed all-day 
accompanies by family members. Percentages of patients needing half-day and 
all-day accompany by family members were higher in ICU and old patients than 
those in general and younger ones(P<0.05). CONCLUSIONS: Patients do need to 
be accompanied in ICU. An all-day accompany by family member is highly 
preferred.  
 
PHS122  
PIT FALLS OF THE NATIONAL HEALTH SERVICE (NHS) “INTERNAL MARKET” 
HEALTH CARE MODEL; DOES REIMBURSEMENT OF SECONDARY CARE MATCH 
COSTS INCURRED  
Wilkinson H, Ma L, Saleh A, Raichura H, Wilson L, Emmanuel J 
Royal London Hospital NHS Trust, London, UK  
OBJECTIVES: Many NHS hospitals have developed an Acute Medicine Unit to 
streamline all non-elective medical admissions. The cost of providing this 
secondary care service is funded by the local primary care team, who in turn 
receive funding from central government. However, teaching hospitals in the 
capitol would also care for a considerable number of international and national 
patients. We sought to examine if health care costs were reimbursed for these 
patients. METHODS: We undertook a retrospective audit of all admissions over a 
6 week period at a central London teaching hospital. We collected patient 
demographics, ICD-10 diagnosis and length of stay. We identified all “out of 
area” patients and calculated costs incurred based on bed days, diagnosis and re-
admission within a month. The ICD-10 codes were converted to cost (HRG) codes 
through the finance office. RESULTS: A total of 864 admissions and 124 
readmissions were analysed. In all 28% (n=242) of admissions were “out of area”. 
This cohort accounted for 25% of bed occupancy, and cost the hospital £390,300. 
Further, 1% (n=8) of patients were of no fixed abode (homeless) and cost £7,200 in 
bed occupancy. The international patients account for 1% (n=6) and cost £4,500 
in bed occupancy. The top 3 presenting complaints with disease management 
costs were; Sickle cell anaemia (n=27-£34,899) chest pain (n=24-£16,757) and 
lower respiratory tract infection (n=19-£69,288). We went on to compare the 
income generated from these admissions on an individual basis. Initial analysis 
point to a deficit in income generated. This has significant implications for the 
financial viability of secondary/tertiary care hospitals in the NHS. 
CONCLUSIONS: Our analysis point to a considerable financial burden from “out 
of area” patients to the capitol’s hospitals. Reducing this financial burden does 
raise clinical and ethical challenges to the receiving hospital.  
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THE EFFECT OF COPAYMENTS FOR PRESCRIPTIONS ON ADHERENCE TO 
MEDICINES IN PUBLICLY INSURED POPULATIONS: A SYSTEMATIC REVIEW 
AND META-ANALYSIS  
Sinnott SJ, Buckley C, O'Riordan D, Bradley C, Whelton H 
University College Cork, Cork, Ireland  
OBJECTIVES: To quantitatively estimate the effect of copayments for 
prescriptions on adherence to medicines in a publicly insured population. 
METHODS: Eight electronic databases and the grey literature were systematically 
searched by one reviewer for relevant articles, along with hand searches of 
references in review articles and the included studies. Studies were included if 
they involved a publicly insured population, an intervention which was the 
introduction of, or an increase in copayment and if the outcome was objectively 
measured adherence (or non-adherence) to medicines. Measures of adherence 
included Proportion of Days Covered and Medication Possession Ratio. Study 
exclusion, data extraction and quality appraisal were carried out by two 
independent reviewers. A random effects model was used to generate the meta-
analysis in RevMan version 5.1. Statistical heterogeneity was assessed using the 
I2 test; p=>0.1 indicated a lack of heterogeneity. RESULTS: Seven out of 41 studies 
met the inclusion criteria. Five studies contributed more than 1 result to the 
meta-analysis. The meta-analysis included 199, 996 people overall; 74, 236 
people in the copayment group and 125,760 people in the non-copayment group. 
Average age was 71.75 years. In the copayment group, (verses the non-
copayment group), the odds ratio for non-adherence was 1.11 (95% CI 1.09-1.14; 
P=<0.00001). An acceptable level of heterogeneity at I2=10%, (p=0.34) was 
observed. CONCLUSIONS: This meta-analysis showed an 11% increased odds of 
non-adherence to medicines in publicly insured populations involved in a 
system where copayments for medicines are necessary. Policy-makers should be 
wary of potential negative clinical outcomes resulting from lack of adherence. 
Unintended economic repercussions of copayments are possible.  
 
PHS124  
REIMBURSEMENT LANDSCAPE AND POLICY DEVELOPMENT FOR RARE 
DISEASES IN CHINA: A CASE STUDY OF HEMOPHILIA  
Chen W, Zhang L 
Fudan University, Shanghai, China  
OBJECTIVES: Hemophilia, a costly yet treatable rare disease, receives 100% 
reimbursement coverage in most developed world and some developing 
countries. The Chinese Ministry of Health announced in 2012 that 20 high-cost 
diseases (including hemophilia) should be prioritized to ease patients’ economic 
burdens. This study aims to understand the current reimbursement landscape 
for hemophilia in China and to explore potential funding mechanisms that could 
be expanded across China to improve reimbursement coverage to meet this 
requirement. METHODS: Hemophilia reimbursement policies of 3 major social 
insurance schemes were collected in 36 cities (provincial capitals and 
municipalities). In-depth interviews were conducted with selected government 
stakeholders to understand the rationale of different policies in different cities 
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and implementation results. RESULTS: Outpatient hemophilia treatment is 
covered by health insurance schemes in more than 80% of the selected cities, yet 
with reimbursement caps and patient co-pay requirements. While there is 
significant variation by city, the average co-pay requirement is more than 50% 
and annual reimbursement is usually capped below USD16k (100k CNY). 
However, some cities have pioneered innovative policies to provide better 
coverage for hemophilia patients: Guangzhou health insurance bureau has 
decreased hemophilia co-payments to less than 10% after their extensive review 
of the economics of hemophilia treatment. The local health insurance bureau in 
Qingdao has decided to joint-fund prophylaxis treatment for pediatric patients 
together with a FVIII manufacturer. CONCLUSIONS: Hemophilia treatment 
reimbursement in China is still at a low level overall despite a few pioneer cities 
which have identified unique approaches to reducing the economic burden of 
patients living with hemophilia. There is significant room to increase 
reimbursement ratio and cap to reduce patients’ economic burden, and 
meanwhile we expect tailored public-private partnerships to be a promising 
supplementing solution.  
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MULTI-PAYERS COMPARISON OF DAILY REIMBURSEMENT VALUES OF 
DISTINCT HOSPITAL FACILITIES IN THE BRAZILIAN PRIVATE HEALTH SYSTEM  
Araújo GTB1, Abicalaffe CL2, Savian J2, Decimoni TC1, Santos AM1, Fonseca M3 
1Axia.Bio Consulting, São Paulo, Brazil, 22iM S/A, Curitiba, Brazil, 3Federal University of São 
Paulo / Axia.Bio Consulting, São Paulo, Brazil  
OBJECTIVES: In the Brazilian public health care system, the government 
establishes one value to reimburse the entire country for the use of different 
health care facilities. In the supplementary/private system, as a business-to-
business negotiation, each the hospital negotiates different reimbursement 
values with each payer for the use of distinct hospital facilities. There are eight 
different types of hospital facilities available in the supplementary system: 
standard, cardiovascular unit, surgery unit, psychiatric, day hospital, nursery, 
adult and pediatric ICU. The objective of this study is to find out and compare 
hospital facilities daily reimbursement values and establish a mean 
reimbursement value for each facility type in the private health care. METHODS: 
Data was obtained from BI.2iM database, a 5 million people sample of the 
Brazilian supplementary health care market. All values are in 2009 Brazilian reais 
(US$1.00 = R$ 2.00). Data are presented as mean±standard deviation RESULTS: 
65% of the patients are from medical cooperatives, HMOs 20%, self-management 
11%, others 4%. A total of 303,573 hospitalizations were reviewed with a total 
expenditure of R$ 82.9 million. The mean reimbursement for each facility type 
was: standard R$ 152.43±R$ 148.80; cardiovascular unit R$ 183.03±R$ 92.63; 
surgery unit R$ 202.06±R$ 87.74; psychiatric R$ 121.42±R$ 50.66; day hospital R$ 
79.60±R$ 23.50; nursery R$ 73.25±R$ 30.67; adult ICU R$ 625.82±R$ 305.71 and 
pediatric ICU R$ 762.91±R$ 330.58. CONCLUSIONS: There is not a single 
reimbursement list (health plans to the providers) or fixed values for hospital 
facilities daily reimbursement values. We found different mean values of 
hospital facilities daily reimbursement that vary according to the facility type. 
Even within the same facility type there is also reimbursement value variation.  
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FACTORS INFLUENCING THE VARIATION IN HOSPITAL INPATIENT PRICES 
BETWEEN PUBLIC AND PRIVATE PAYERS  
Maeda JL1, Henke RM2, Marder WD2, Friedman BS3, Wong H4 
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OBJECTIVES: The large variation in payments hospitals receive for similar 
services has captured the attention of payers and policy-makers looking for ways 
to curb excess health care spending. There is little empirical evidence regarding 
the specific role that patient, population, and market factors might have in 
driving price variation across small geographic areas and how these factors vary 
by payer. The purposes of this study are: (1) to provide insight into the 
relationship between patient, population, and market factors and payer-specific 
prices for several common conditions, and (2) to examine the factors that 
influence differences in the inpatient price per discharge between public 
(Medicare) and private payers among different hospital services. METHODS: We 
extracted hospital data from six states where a Healthcare Cost and Utilization 
Project (HCUP) price-to-charge ratio (PCR) was available from the 2006 State 
Inpatient Databases (SID). Even in states with PCR data, the PCR was not 
available for Kaiser Permanente hospitals so those discharges were excluded. 
The price per discharge was measured at the county-level for all discharges, an 
acute condition (acute myocardial infarction), and an elective condition (knee 
arthroplasty). Payer-specific inpatient prices were estimated by applying the 
HCUP PCR to total hospital charges. Ordinary least squares regression models 
were used to identify factors significantly associated with inpatient price per 
discharge by payer. RESULTS: Hospitals charged significantly higher prices to 
private payers compared to public payers. There was more variation in price per 
discharge for private payers compared to public payers for most hospital 
services. Specific market factors, including hospital competition, were associated 
with the price variation between payers. CONCLUSIONS: The larger variation in 
the price per discharge identified among private payers necessitates further 
exploration. It may stem from differences in negotiated prices and market power 
across small geographic areas, or the price restraints of public payers.  
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IN VITRO FERTILIZATION (IVF): GLOBAL TRENDS IN MARKET DYNAMICS AND 
REIMBURSEMENT POLICIES  
Meyrowitz S1, Bastian AW1, Patel A2 
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OBJECTIVES: To understand IVF policy landscape, reimbursement and access to 
treatment in the global health markets, and trends and drivers of change, for the 
purpose of identifying markets likely to support reproductive health franchises. 
METHODS: IVF ecosystems were assessed in 19 countries. We conducted a 
thorough review of published literature pertaining to Assisted Reproductive 
Technology (ART) policy, reviewed infertility organization and clinic websites 
and associated publications. Key market differences impacting the IVF 
environment were identified and analyzed for comparison. RESULTS: 
Opportunities in IVF must consider reimbursement policy, cultural influences, 
and med-tourism. While the US is one of the most advanced markets with 
respect to number of IVF cycles, technologies utilized, and cultural trends, 
healthplans provide no reimbursement and most patients pay 100% out-of-
pocket (OOP). Elsewhere, reimbursement varies greatly: Israel and European 
countries tend to provide more generous reimbursement than Latin America and 
Africa, however restrictions and requirements can greatly limit the coverage. 
Recent legislation changes in European markets have expanded reimbursement, 
and changes in South America are likely to evolve as reproductive health 
awareness and access to infertility treatment becomes more widespread. Finally, 
many patients do seek treatment abroad due to lower costs, shorter waitlists, 
and fewer restrictions: South America, South Africa, and Israel tend to be sought 
after destinations for patients willing to pay OOP. CONCLUSIONS: Reproductive 
health is unlike other therapeutic areas because reimbursement, alone, is 
insufficient to assess opportunity. Given the breadth of this poorly reimbursed 
therapeutic area, stakeholders must seek to appreciate the impact of cultural 
trends and med-tourism, including: declining birth rates, increasing access to 
IVF and reproductive health awareness, improvements in local economies and 
reforms to public policy. Manufacturers and policy makers should prepare to 
understand evolving market access and patient environments to effectively 
prioritize traditionally overlooked countries as key factors shift in the coming 
years.  
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IMPLEMENTATION OF QUALITY IMPROVEMENT INTERVENTIONS FOR 
PRESSURE ULCER PREVENTION IN UNIVERSITY HEALTHSYSTEM CONSORTIUM 
HOSPITALS  
Padula WV1, Mishra MK2, Makic MBF3, Nair KV4, Campbell J5, Wald H5,  
Valuck R6 
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USA, 3University of Colorado Hospital, Aurora, CO, USA, 4University of Colorado, Denver, 
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OBJECTIVES: Quantify adoption patterns of quality improvement (QI) 
interventions designed to support evidence-based guidelines for hospital-
acquired pressure ulcer (HAPU) prevention. METHODS: We surveyed wound care 
nurses at 180 University HealthSystem Consortium (UHC) hospitals to determine 
which QI interventions were included in HAPU prevention protocols. The 
validated questionnaire organized 29 HAPU-specific QI interventions into four 
domains: Leadership; Staff; Information Technology (IT); and Performance & 
Improvement (P&I). Respondents checked QI interventions implemented 
anytime between 2007-2012. Descriptive statistics evaluated patterns of QI 
adoption and t-tests established statistically significant (p>0.05) increases in 
adoption. The points of time evaluated for QI adoption were 3rd-quarter, 2008 
when changes to Medicare policy discontinued HAPU reimbursement, and 2nd-
quarter, 2012. Increases were described in terms of scope (number of QI domains 
employed) and scale (number of QI interventions within domains). RESULTS: 
Fifty-five (30.6%) hospitals responded to the survey. Fifty-three (96%) hospitals 
implemented QI with HAPU prevention. Leadership interventions were most 
frequent, increasing in scope from 40-63% between 2008-2012; scale increased 
significantly for all leadership interventions, with “annual programs to promote 
pressure ulcer prevention” showing the greatest increase. Staff interventions 
increased in scope from 32-53%; signficant increases in scale occurred for six-of-
seven interventions, with “frequent consult driven huddles” undergoing the 
greatest increase. IT interventions increased in scope from 31-55%, and all five IT 
interventions increased significantly. Establishing an electronic HAPU 
trigger/alarm for high-risk patients accounted for the greatest adoption. P&I 
interventions increased in scope from 18-40%. Seven-of-nine P&I interventions 
had significant increases in scale, with “new skin care products…” increasing the 
most. CONCLUSIONS: UHC hospitals increased adoption of QI interventions, 
including scope and scale of QI strategies, since changes in Medicare policy to 
support HAPU prevention protocols and make use of novel technology and 
medical products. The next step in this research is to compare the effectiveness 
of different QI interventions.  
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THE RELATIONSHIP BETWEEN LOCAL FAMILY PHYSICIAN SUPPLY AND 
POPULATION HEALTH STATUS IN THE FEDERAL REGIONS IN THE UNITED 
STATES  
Zhao Y1, Gu NY2 
1University of New Mexico, ALBUQUERQUE, NM, USA, 2University of New Mexico, Albuquerque, 
NM, USA  
OBJECTIVES: Due to emerging health care crisis of nationwide sharp decline in 
family physician (FP) supply, this study investigates the relationship between the 
supply of local FP workforce and the general population health status in the US 
federal regions. METHODS: A cross-sectional study was performed by merging 
the individual-level data from the 2009 Behavioral Risk Factor Surveillance 
System (BRFSS) with the county-level data from the 2011-2012 Area Resource File 
